Atreca (Atreca) Debt-to-Equity : 0.12 (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Atreca Debt-to-Equity?

Atreca's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.28 Mil. Atreca's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Atreca's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $10.76 Mil. Atreca's debt to equity for the quarter that ended in Sep. 2023 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Atreca's Debt-to-Equity or its related term are showing as below:

BCEL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.52 Max: 1.39
Current: 0.12

During the past 6 years, the highest Debt-to-Equity Ratio of Atreca was 1.39. The lowest was 0.00. And the median was 0.52.

BCEL's Debt-to-Equity is ranked better than
55.47% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs BCEL: 0.12

Atreca Debt-to-Equity Historical Data

The historical data trend for Atreca's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca Debt-to-Equity Chart

Atreca Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.82

Atreca Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.67	0.82	1.03	1.39	0.12

Competitive Comparison of Atreca's Debt-to-Equity

For the Biotechnology subindustry, Atreca's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atreca's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atreca's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Atreca's Debt-to-Equity falls into.

Atreca Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Atreca's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.544	+	60.331)	/	78.406
	=	0.81

Atreca's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.281	+	0)	/	10.759
	=	0.12

Atreca (OTCPK:BCEL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Atreca Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Atreca's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Atreca (Atreca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (OTCPK:BCEL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0C1:Germany

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.atreca.com

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Executives

Felix Baker	other: Former 10% Owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	other: Former 10% Owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	other: Former 10% Owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	other: Former 10% Owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Roger Richard Ruiz	officer: VP of Finance	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Stephen E Gould	officer: Chief Scientific Officer	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Tito Serafini	director, officer: Chief Strategy Officer	C/O ATRECA, INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Phillips Courtney	officer: General Counsel & Secretary	ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Philippe C Bishop	officer: Chief Medical Officer	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
John A Orwin	director, officer: President & CEO	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Stacey Ma	director	C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS CA 94070
Stephen R Brady	director	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Norman Michael Greenberg	officer: Chief Scientific Officer	500 SAGINAW DRIVE, REDWOOD CITY CA 94063
William Hewitt Robinson	director	500 SAGINAW DRIVE, REDWOOD CITY CA 94063